CAS: 480-56-8; Lecanoric Acid

上下游产品

1-methyl-4-nitrosobenzene umbilicaric acid gyrophoric acid orsellinic acid3-hydroxy-4-(methoxycarbonyl)-5-methylphenyl-2,4-dihydroxy-6-methylbenzoate methyl orsellinate propyl 2,4-dihydroxy-6-methylbenzoate °Ctyl-2,4-dihydroxy-6-methyl benzoate

📜2,4-二羟基-6-甲基苯甲酸置于sodium Hydroxide,丙酮体系中,化学反应生成 红粉苔酸
参考文献:Patients' Views On Out-Of-Hours Care In General Practice In Dublin
标题:Patients' Views On Out-Of-Hours Care In General Practice In Dublin
摘要:Background Little Is Known Regarding Patients' Views And Levels Of Satisfaction With Out-Of-Hours Care In Irish General Practice Despite Significant Recent Changes In Service Delivery.Aims This Study Aimed To Record Patients' Experience Of Out-Of-Hours Care On A Specific occasion And Elicit Their Satisfaction With Out-Of-Hours Care In General.Methods Patients Requesting Out-Of-Hours Care In Three South Inner City Dublin Practices In June And July 2000 Were Identified And Sent An Anonymous Postal Questionnaire.Results Two Hundred And Forty Patients Were Identified And 58% Responded To The Questionnaire,The Approximate Call Rate Was 195 Calls Per 1,000 Patients Per Year. Sixty-One Per Cent Of Patients Used The Co-Operative Service,28% Received A House Call And 3% Received Telephone Advice Only; 86% Are Currently Satisfied With Out-Of-Hours Care.Conclusions The Majority Of Patients Are Satisfied With The Current Out-Of-Hours Service. Telephone Consultation Rates Are Significantly Lower Than Other Countries. These Findings Need To Be Considered Before The Widespread Introduction Of Systems Involving Increased Telephone Consultations.
DOI:10.1007/bf03173889

专利信息

专利号:US-2004110228-A1
优先权日:2002-04-01
标 题:Combinatorial organic synthesis of unique biologically active compounds
发明人：MCALPINE SHELLI R; TAYLOR RACHEL E; BOLLA MEGAN L; SEGALL ANCA M
摘要:The invention provides a method for making a combinatorial library of cyclic compounds, such as Holliday junction-trapping compounds, comprising the steps of (a) obtaining a plurality of trimers according to the generic structure X 1- X 2- X 3 , wherein X 1 , X 2 and X 3 can be independently any naturally or nonnaturally occurring amino acids or peptidomimetics thereof; (b) optionally coupling a spacer S to the trimer at either end; (c) cyclizing two trimers or trimer-spacer conjugates in a head-to-tail orientation; thereby obtaining a combinatorial library of compounds, wherein the library does not include an unmodifed or naturally occurring Holliday Junction-trapping compounds. The invention additionally provides methods macrocyclic compounds that are synergimycin derivatives.

专利号:US-2005080260-A1
优先权日:2003-04-22
标 题 :Preparation of prodrugs for selective drug delivery
发明人：MILLS RANDELL L; WU GUO-ZHANG
摘要:Synthesis of a chemical compound having the formula A-B-C that may serve for applications such as drug delivery where A is a chemiluminescent, moiety, B is a photochromic moiety, and C is a biologically active moiety where A-B-C may serve as a prodrug. Novel synthetic methods of the present invention to form the prodrug comprised the steps of (1) forming a benzophenone, (2) forming a diaryl ethylene, (3) attaching a phthalimide moiety to at least one of the aryl groups of the ethylene to form a phthalimide-ethylene conjugate, (4) condensing two ethylene-phthalimide conjugates to form a phthalimide-pentadiene conjugate, (5) converting the phthalimide to the phthalhydrazide by reaction with hydrazine to form a carrier compound according to the present invention, and (6) reacting the carrier compound with an nucleophilic moiety of the drug to form the corresponding prodrug. Alternatively the carrier can be prepared by using the halo-substituted diaryl ethylene to make the corresponding cationic leuco dye-like compound with known methods. The cationic compound then is protected by reacting with a nucleophile and coupled with the aminophathalimide by palladium-catalyzed amination to form the protected phthalimide-pentadiene conjugate. The latter is refluxed with hydrazine to convert its phthalimide to the phthalhydrazide and acidified to give the carrier. An additional aspect of the present invention relates to the use of these compounds as antiviral agents for the treatment of viral infections such as HIV and as anticancer agents for the treatment of cancers such as bowel, lung, and breast cancer.